摘要
目的:观察并分析研究生血宝合剂联合扶正消瘤饮对化疗所致骨髓抑制的疗效。方法:选择符合标准的接受化疗的脾胃气虚型患者共80例,随机分对照组、治疗组各40例,对照组在化疗后第二天开始予生血宝合剂口服,连续服用2周,治疗组在上述处理上在联合扶正消瘤饮,服用上药前后分别进行KPS评分、骨髓抑制程度、血常规检测。结果:与对照组相比较,治疗组患者的中医症状明显改善,KPS总评分明显高于对照组,血常规提示三系减少数值低于对照组,差异有统计学意义(P<0.05),且治疗过程中均未出现严重不良反应。结论:临床上运用"生血宝合剂联合扶正消瘤饮"能明显改善患者生活质量、降低骨髓抑制的程度。
Objective:To observe and analyze the curative effect of Shengxuebao mixture combined with Fuzheng Xiaoliu decoction on myelosuppression induced by chemotherapy.Methods:A total of 80 patients with spleen-stomach-qi deficiency type who received chemotherapy were selected and were randomly divided into control group and treatment group with 40 cases each.The control group was given Shengxuebao mixture orally on the second day after chemotherapy for 2 weeks.The treatment group In the above treatment,combined with Fuzheng Xiaoliu decoction,KPS score,bone marrow suppression,and blood routine tests were performed before and after taking the medicine.Results:Compared with the control group,the TCM symptoms of the patients in the treatment group were significantly improved.The total KPS score was significantly higher than that of the control group.The blood routine showed that the three-line reduction value was lower than the control group.The difference was statistically significant (P<0.05).No serious adverse reactions occurred during the treatment.Conclusion:The clinical application of "Shengxuebao mixture and Fuzheng Xiaoliu decoction" can significantly improve the quality of life of patients and reduce the degree of bone marrow suppression.
作者
刘洋
李文静
查名宝
LIU Yang;ZHA Mingbao(Anhui University of Chinese Medicine,Anhui Hefei 230038,China;Postgraduate training base of Wuhu Hospital of traditional Chinese medicine of Anhui University of Chinese Medicine,Anhui Wuhu 241000,China;Traditional Chinese Medicine Hospital of Wuhu City,Anhui Wuhu 241000,China)
出处
《中医药临床杂志》
2020年第9期1738-1741,共4页
Clinical Journal of Traditional Chinese Medicine
基金
安徽省十二五省级重点中医专科建设单位。
关键词
生血宝合剂
扶正消瘤饮
化疗
骨髓抑制
肿瘤
Shengxuebao mixture
Fuzheng Xiaoliu decoction
Chemotherapy
Bone Marrow inhibition
Tumor
